AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01439230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept®
Description: 10 mg Tablet
Study NCT00417404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aquasol A
Description: IM Aquasol A 10,000IU three times weekly
Study NCT01011946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography
Description: Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
Study NCT04222946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
Study NCT03427034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BladderLight®
Description: Using a cell collection device to look for the presence of bladder cancer cells
Study NCT04818931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin Injection
Description: cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
Study NCT01644916 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Integrated care
Description: Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
Study NCT01644916 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual control
Description: Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
Study NCT02057939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: 160 mg orally once daily for six months
Study NCT02057939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation
Description: Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
Study NCT02057939 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
Study NCT00344760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: subcutaneously twice a day
Study NCT00344760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz, lamivudine, and tenofovir
Description: Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
Study NCT00344760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz, lamivudine, and tenofovir
Description: Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
Study NCT02249026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZDs + opiate exposure treated with BPN
Description: These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
Study NCT02249026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opiates exposure treated with BPN
Description: These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
Study NCT01655745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG PET/MR
Description: All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
Study NCT03854851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldebain
Description: In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.
Study NCT03854851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morpine
Description: In Morphine group, patients will receive morphine as needed after surgery.
Study NCT01170221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
Study NCT01170221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Oral Linezolid 600 mg twice daily for 10 days
Study NCT04373213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pleth variability index
Description: The usefulness of Pleth variability index in predicting fluid response in patients with COVID 19
Study NCT04179019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks
Study NCT02899624 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extra blood draw samples
Study NCT02899624 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Extra blood draw samples
Study NCT02899624 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: additional tissue samples
Study NCT02899624 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: additional tissue samples
Study NCT01045928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT01045928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01045928 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative study
Study NCT01045928 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative study
Study NCT01045928 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative study
Study NCT02702154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Description: 20 Hz active stimulation, twice daily
Study NCT02702154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS
Description: 1 Hz active stimulation, twice daily
Study NCT02702154 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham stimulation, twice daily
Study NCT00773656 — intervention group
Intervention type: OTHER
Intervention: Whole blood sample
Description: 70 ml per patient for collection of biological sample
Study NCT01045928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative study
Study NCT01045928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT02613520 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge (for CHMI)
Description: live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Study NCT04489004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Driver ablation+CPVI
Description: Patients receive driver ablation and CPVI (circumferential pulmonary vein isolation).
Study NCT04489004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepwise ablation
Description: Patients receive stepwise ablation.
Study NCT02347852 — intervention group
Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
Study NCT03530202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
Study NCT03530202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin Powder
Description: Participants will consume Maltodextrin Powder (Globe Plus 10 DE Maltodextrin Powder, Univar Canada) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water. On non-training days, supplements will be consumed at the participant's leisure.
Study NCT04000022 — intervention group
Intervention type: DEVICE
Intervention: intermittent theta burst stimulation (iTBS)
Description: 20 sessions of iTBS
Study NCT01605201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tissue engineered cartilage graft
Description: Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
Study NCT03796884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Given PO
Study NCT03796884 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT04095442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cepacol
Description: Twice-daily use of Cepacol per the manufacturer's guidelines
Study NCT00198328 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Medpulser Electroporation with Bleomycin
Description: Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
Study NCT00198328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Excision
Description: Patients have their tumor surgically removed.
Study NCT01490918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose 50mg b.i.d at first, at the 2nd week 50mg t.i.d and the 4th week, 100mg tid.
Study NCT01490918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acarbose
Description: acarbose placebo
Study NCT01490918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo metformin
Description: metformin placebo
Study NCT03659110 — intervention group
Intervention type: BIOLOGICAL
Intervention: HPV 4
Description: 1000 subjects will be received the HPV 4 vaccine
Study NCT00898170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myoma removal
Description: surgical removal of myoma by hysterectomy
Study NCT06160141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training program. The RT program was performed over 48 weeks, three times per week (Mondays, Wednesdays, and Fridays), during the morning, in the University fitness facility. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise) with substantial RT experience to ensure consistent and safe exercise performance.~Participants performed four exercises for the trunk and upper limbs and four exercises for the lower limbs in three sets of 8-12 repetitions. T Rest intervals were 1-2 and 2-3 min between sets and exercises. The training load was individually adjusted for each exercise weekly, according to the number of repetitions performed during the last training session, to ensure that the subjects kept performing at the ideal intensity for the repetition zone. In these situations, training loads were increased by 2-5% for upper-limb exercises and 5-10% for lower-limb exercises.
Study NCT03117959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker ShapeMatch Technology
Description: Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.
Study NCT03117959 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stryker Triathlon Custom Fit Knee
Study NCT04095442 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tom's Natural Mouthwash
Description: Twice-daily use of Tom's Natural Mouthwash per the manufacturer's guidelines
Study NCT02223429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
Study NCT02223429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: 1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
Study NCT02223429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
Study NCT04681729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study NCT04681729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study NCT04681729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non sedating H1-antihistamine
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT04681729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non sedating H1-antihistamine
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT02757092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Pulmonary Rehabilitation
Description: (1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
Study NCT02757092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Pulmonary Rehabilitation
Description: (1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
Study NCT03148587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-assessment: MLPT
Description: Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.
Study NCT03148587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-assessment: LSPT
Description: Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.
Study NCT00908622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous autologous myoblast implantation
Description: Endocavity implantation of autologous myoblasts
Study NCT00908622 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac revascularization
Description: Cardiac revascularization
Study NCT04159818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards
Study NCT04159818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40mg/m2, weekly for two weeks
Study NCT04159818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose doxorubicin
Description: 15mg flat dose, weekly for 8 weeks
Study NCT02006498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sillymarin
Description: Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
Study NCT02006498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule with same appearances as study drug
Study NCT03970018 — intervention group
Intervention type: OTHER
Intervention: Intra-peritoneal pressure
Description: Measurement of intra-peritoneal pressure
Study NCT01759160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marsh Plasma TCI with high initial target
Description: plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
Study NCT01759160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Schnider Plasma TCI with high initial target
Description: plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
Study NCT03690947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab
Description: All subjections received 3 initial Ranibizumab injections
Study NCT03690947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Ranibizumab
Description: All subjections received 3 initial Ranibizumab injections
Study NCT03690947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micropulse Laser
Description: After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists
Study NCT03690947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Ranibizumab as needed
Description: After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
Study NCT03167541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test
Description: RB naproxen sodium tablets (2x220mg)
Study NCT03167541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference
Description: Aleve naproxen sodium tablets (2x220mg)
Study NCT03464890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P926 - LICHTENA DermAD CREMA VISO
Description: The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
Study NCT03464890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P927 - LICHTENA DermAD CREMA CORPO
Description: The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
Study NCT03464890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P926 - LICHTENA DermAD CREMA VISO - PLACEBO
Description: The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
Study NCT03464890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated control area
Description: Untreated skin area of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
Study NCT03079557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intragastric botulinum toxin type A
Description: 200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months